Can we help?

call us on +44 (0)131 4456077
or email

share this print page

Investor relations

Bespoke solutions from clinical trial to launch

Investor relations

News


13/03/2013 Resignation of Nominated Adviser
11/02/2013 Appointment of administrators
08/02/2013 Suspension - Angel Biotechnology Holdings Plc
08/02/2013 Statement re. Suspension
28/01/2013 General Meeting Statement
28/12/2012 Update and Notice of General Meeting
10/12/2012 Interim Results
03/12/2012 Publication of interims and update on JV
05/11/2012 Angel sign new contract with ReNeuron
19/10/2012 Trading Update
12/10/2012 Board Changes
14/09/2012 Operational Review and Market Update
29/08/2012 Angel and arGentis sign Framework Agreement
12/07/2012 Result of AGM
25/06/2012 Successful Completion of MHRA Inspection
21/06/2012 Notice of AGM
01/06/2012 Final Results
29/05/2012 Successful Completion of MHRA Inspection
16/05/2012 Angel signs new contract with ReNeuron
16/05/2012 Cell Manufacturing Contract
15/05/2012 Angel Biomedical Ltd announces supply agreement
10/05/2012 Acquisition of assets
26/04/2012 Holding(s) in Company
17/04/2012 Angel and TransGenRx Inc. sign contract
13/04/2012 Result of EGM
26/03/2012 Update on Cramlington
19/03/2012 Notice of EGM and Proposed Placing
05/03/2012 Appointment of acting CEO
02/03/2012 Directorate Change
27/02/2012 Grant of Share Options
06/02/2012 Contracts with Materia Medica
16/01/2012 Holding(s) in Company
10/01/2012 Trading Update
22/12/2011 Placing
16/12/2011 Framework Agreement with TransGenRx Inc.
07/12/2011 UK Government Life Sciences Strategy
05/12/2011 Appointment of Commercial Director
17/10/2011 Intent to establish joint venture operation
23/09/2011 Change of Adviser
17/08/2011 Share Option Awards
25/07/2011 Appointment of WH Partnership re Cramlington
18/07/2011 Half Yearly Report
14/07/2011 Angel signs US consultancy agreement with BPTC
06/07/2011 Change of Accounting Reference Date
05/07/2011 Angel signs new contract with ReNeuron
05/07/2011 Contract with Angel Biotechnology Holdings plc
01/07/2011 Exercise of Options
14/06/2011 Angel's expertise assists Azellon
08/06/2011 Result of AGM
Last updated: 09:33 23/05/2013

Learn more

Contact us

for investor relations queries:
enquiries@angelbio.com

Our services

Along with the successful production of recombinants, Angel provides development and process scale-up strategies

Our services